IDEAS home Printed from https://ideas.repec.org/a/nat/nature/v543y2017i7646d10.1038_nature21435.html
   My bibliography  Save this article

Early antibody therapy can induce long-lasting immunity to SHIV

Author

Listed:
  • Yoshiaki Nishimura

    (Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health)

  • Rajeev Gautam

    (Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health)

  • Tae-Wook Chun

    (Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health)

  • Reza Sadjadpour

    (Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health)

  • Kathryn E. Foulds

    (Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health)

  • Masashi Shingai

    (Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health)

  • Florian Klein

    (Institute of Virology, University of Cologne
    Center for Molecular Medicine Cologne (CMMC), University of Cologne)

  • Anna Gazumyan

    (Laboratory of Molecular Immunology, The Rockefeller University)

  • Jovana Golijanin

    (Laboratory of Molecular Immunology, The Rockefeller University)

  • Mitzi Donaldson

    (Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health)

  • Olivia K. Donau

    (Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health)

  • Ronald J. Plishka

    (Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health)

  • Alicia Buckler-White

    (Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health)

  • Michael S. Seaman

    (Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center)

  • Jeffrey D. Lifson

    (AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research)

  • Richard A. Koup

    (Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health)

  • Anthony S. Fauci

    (Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health)

  • Michel C. Nussenzweig

    (Laboratory of Molecular Immunology, The Rockefeller University
    Howard Hughes Medical Institute, The Rockefeller University)

  • Malcolm A. Martin

    (Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health)

Abstract

Early administration of broadly neutralizing antibodies in a macaque SHIV infection model is associated with very low levels of persistent viraemia, which leads to the establishment of T-cell immunity and resultant long-term infection control.

Suggested Citation

  • Yoshiaki Nishimura & Rajeev Gautam & Tae-Wook Chun & Reza Sadjadpour & Kathryn E. Foulds & Masashi Shingai & Florian Klein & Anna Gazumyan & Jovana Golijanin & Mitzi Donaldson & Olivia K. Donau & Rona, 2017. "Early antibody therapy can induce long-lasting immunity to SHIV," Nature, Nature, vol. 543(7646), pages 559-563, March.
    • Handle: RePEc:nat:nature:v:543:y:2017:i:7646:d:10.1038_nature21435
    DOI: 10.1038/nature21435
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/nature21435
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1038/nature21435?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Christoph Kreer & Cosimo Lupo & Meryem S. Ercanoglu & Lutz Gieselmann & Natanael Spisak & Jan Grossbach & Maike Schlotz & Philipp Schommers & Henning Gruell & Leona Dold & Andreas Beyer & Armita Nourm, 2023. "Probabilities of developing HIV-1 bNAb sequence features in uninfected and chronically infected individuals," Nature Communications, Nature, vol. 14(1), pages 1-14, December.
    2. Caroline Passaes & Delphine Desjardins & Anaïs Chapel & Valérie Monceaux & Julien Lemaitre & Adeline Mélard & Federico Perdomo-Celis & Cyril Planchais & Maël Gourvès & Nastasia Dimant & Annie David & , 2024. "Early antiretroviral therapy favors post-treatment SIV control associated with the expansion of enhanced memory CD8+ T-cells," Nature Communications, Nature, vol. 15(1), pages 1-19, December.
    3. Miriam Rosás-Umbert & Jesper D. Gunst & Marie H. Pahus & Rikke Olesen & Mariane Schleimann & Paul W. Denton & Victor Ramos & Adam Ward & Natalie N. Kinloch & Dennis C. Copertino & Tuixent Escribà & An, 2022. "Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8+ T cell immunity," Nature Communications, Nature, vol. 13(1), pages 1-12, December.
    4. Daniel B. Reeves & Bryan T. Mayer & Allan C. deCamp & Yunda Huang & Bo Zhang & Lindsay N. Carpp & Craig A. Magaret & Michal Juraska & Peter B. Gilbert & David C. Montefiori & Katharine J. Bar & E. Fab, 2023. "High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials," Nature Communications, Nature, vol. 14(1), pages 1-15, December.
    5. Victoria E. K. Walker-Sperling & Noe B. Mercado & Abishek Chandrashekar & Erica N. Borducchi & Jinyan Liu & Joseph P. Nkolola & Mark Lewis & Jeffrey P. Murry & Yunling Yang & Romas Geleziunas & Merlin, 2022. "Therapeutic efficacy of combined active and passive immunization in ART-suppressed, SHIV-infected rhesus macaques," Nature Communications, Nature, vol. 13(1), pages 1-8, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:543:y:2017:i:7646:d:10.1038_nature21435. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.